Holen Sie sich die Stockscreener-App
59.49
3.77%
-2.33
Handel nachbörslich:
59.31
-0.18
-0.30%
Schlusskurs vom Vortag:
$61.82
Offen:
$61.46
24-Stunden-Volumen:
4.94M
Relative Volume:
0.67
Marktkapitalisierung:
$23.60B
Einnahmen:
$2.23B
Nettoeinkommen (Verlust:
$-3.19B
KGV:
-7.3028
EPS:
-8.1462
Netto-Cashflow:
$-1.60B
1W Leistung:
-11.22%
1M Leistung:
-6.99%
6M Leistung:
+38.35%
1J Leistung:
+90.31%
1-Tages-Spanne:
$59.30
$62.43
1-Wochen-Bereich:
$59.30
$68.49
52-Wochen-Spanne:
$22.28
$85.60
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
59.49 | 24.53B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
480.50 | 123.26B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.15 | 70.94B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.19 | 53.84B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
180.39 | 39.58B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
272.67 | 35.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Equal Weight |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-12 | Eingeleitet | Jefferies | Hold |
| 2025-03-13 | Eingeleitet | Citigroup | Neutral |
| 2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
Moderna, Inc.'s Stock Price Drops to $59.49, a Decline of 3.77%, Investors Eye Market Performance Closely - Smartkarma
Moderna says CureVac broke agreement by suing over COVID vaccine patents - Reuters
Moderna stock steadies as RSV and COVID vaccine revenues reshape outlook - Ad-hoc-news.de
Moderna counters CureVac patent lawsuit over Covid-19 vaccines By Investing.com - Investing.com Canada
Goldman Sachs Adjusts Moderna Price Target to $67 From $49, Maintains Neutral Rating - marketscreener.com
Wolfe Research raises Moderna stock price target to $25 on updates - Investing.com
D.A. Davidson & CO. Decreases Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna stock edges higher as Spikevax sales stabilize and pipeline spending stays elevated - ad-hoc-news.de
The mRNA-1345 RSV vaccine candidateModerna Inc. bets on older adults - ad-hoc-news.de
US Seeks Toss Of Arbutus Patent Suit Over Moderna Vaccine - Law360
Moderna stock trades lower as COVID vaccine demand weighs on 2026 outlook - ad-hoc-news.de
Moderna (MRNA): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various Indexes - GlobeNewswire Inc.
Moderna stock trades steadily as mRNA pipeline and COVID revenues shape outlook - ad-hoc-news.de
Fed. Circ. Asked Not To Shift Moderna Vax Patent Case To Gov't - Law360
Form 4 Moderna Inc For: 16 July By Investing.com - Investing.com Nigeria
Moderna, Inc.’s Stock Price Plummets to $63.15, Marking a Significant 7.51% Decline - Smartkarma
Moderna president Stephen Hoge sells $3.6m in stock - Investing.com
Moderna, Inc. (MRNA) president exercises options and sells 53,336 shares under 10b5-1 plan - Stock Titan
Lobbying Update: $290,000 of MODERNA INC. lobbying was just disclosed - Quiver Quantitative
ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection? - Stocktwits
The mRESVAI trial for RSV vaccine by Moderna Inc.early data underline a strategic bet on respirat - ad-hoc-news.de
Moderna advances its cancer therapy assessment, but the stock slides - marketscreener.com
ETFs Investing in Moderna, Inc. Stocks - TradingView
Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors - Investing News Network
(MRNA) Risk Channels and Responsive Allocation - Stock Traders Daily
Arbutus Files More Patent Infringement Suits Against Pfizer, BioNTech -- Update - marketscreener.com
Moderna (MRNA) Begins Trial for New Cancer Immunotherapy - GuruFocus
Arbutus (ABUS) Secures $178 Million Settlement with Moderna - GuruFocus
Moderna doses first patient in cancer therapy trial - Investing.com
Arbutus Biopharma Files International Patent Lawsuits Against Pfizer and BioNTech, Announces Moderna Settlement Payment and Plans for Capital Return - Quiver Quantitative
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders - The Manila Times
Arbutus Biopharma (Nasdaq: ABUS) receives $178M from Moderna, eyes $230M buyback - Stock Titan
Moderna Trial Tests Cancer Therapy Encoding Seven Antigens - Stock Titan
Sanofi sues Pfizer, Moderna over COVID shot technology - Reuters
Sanofi Sues Moderna, Pfizer for Vaccine-Tech Patent Royalties - Bloomberg Law News
Form 144 Moderna For: 15 July By Investing.com - Investing.com Canada
Moderna (NASDAQ: MRNA) holder Stephen Hoge plans 53,336-share sale - Stock Titan
Moderna's Ambitious Pivot: Why Its Science Day Vision Outruns Today's Valuation - Kavout | AI
Sanofi Says Pfizer, Moderna COVID Jabs Infringe MRNA Tech - Law360
Gov't Shouldn't Face Vax Suit Targeting Moderna, Group Says - Law360
Moderna set for uneventful Q2 report ahead of key data readouts, says Jefferies - Yahoo Finance
Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance Singapore
Moderna, Takeda and Capricor on the verge of notching big drug approvals - Pharma Voice
The mRESV-101 vaccine candidateModerna Inc. bets on RSV protection in older adults - Ad Hoc News
Jefferies Adjusts Price Target on Moderna to $60 From $53, Maintains Hold Rating - marketscreener.com
What It Means To Hold Moderna Stock In A Crash - Yahoo Finance
Weekly Recap: Moderna names Michael McDonnell to board and $950M patent payout - TradingView
Y Intercept Hong Kong Ltd Sells 444,343 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna Inc (MRNA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Moderna, Inc. (NASDAQ:MRNA) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):